《抗菌藥物化療雜志》是國(guó)際上最重要的抗菌藥物研究期刊之一。我們的讀者包括學(xué)術(shù)界、工業(yè)界和衛(wèi)生服務(wù)部門(mén)的代表，也包括那些在制定決策方面有影響力的人。該雜志每月出版一期，刊載有關(guān)實(shí)驗(yàn)室方面和抗菌藥物臨床應(yīng)用的原創(chuàng)文章，包括抗菌、抗病毒、抗真菌和抗原性藥物。除了豐富的初級(jí)論文外，該雜志還刊載評(píng)論文章，就當(dāng)前關(guān)注的問(wèn)題進(jìn)行深入討論。生動(dòng)的領(lǐng)先文章提供了最近的進(jìn)展和爭(zhēng)議的尖銳報(bào)道。其他部分包括:國(guó)際評(píng)論討論有爭(zhēng)議的問(wèn)題和想法抗菌實(shí)踐文章實(shí)際處方和規(guī)定的問(wèn)題對(duì)應(yīng)部分科學(xué)家提出的早期觀察他們的工作和評(píng)論文章發(fā)表書(shū)評(píng)有用的評(píng)論相關(guān)新出版的頭銜精心組織格式指引你感興趣的領(lǐng)域。每月一期可包含多達(dá)10個(gè)信息性部分:主要文章評(píng)論Garrod演講辯論原始文章摘要報(bào)告抗菌實(shí)踐會(huì)議報(bào)告通信書(shū)評(píng)雜志每年出版2至8個(gè)增刊。這些包括英國(guó)抗微生物藥物化療學(xué)會(huì)的工作組報(bào)告和關(guān)于正在開(kāi)發(fā)的藥物的臨床前和臨床方面的原始出版物，或已建立的藥物在特定治療領(lǐng)域的作用。

The Journal of Antimicrobial Chemotherapy is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia industry and health services and includes those who are influential in formulary decisions. Published monthly the Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial antiviral antifungal and antiprotozoal agents. In addition to the wealth of primary papers the journal carries review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies. Other sections include: For debate International comment on contentious issues and ideas Antimicrobial practice Articles on practical prescribing and formulary issues Correspondence A section for scientists to present early observations of their work and to comment on published articles Book reviews Helpful reviews of relevant newly published titles A carefully organised format directs you to areas of interest. Monthly issues can include up to ten informative sections: Leading articles Reviews The Garrod Lecture For debate Original articles Brief reports Antimicrobial practice Meeting reports Correspondence Book reviews The Journal publishes between two and eight supplements each year. These include Working Party reports of the British Society for Antimicrobial Chemotherapy and original publications on pre-clinical and clinical aspects of drugs in development or the role of established drugs in specific therapeutic areas.